# Harry Erba
Nangungunang mga yugto ng podcast
Nai-update:
Top podcast episodes featuring harry erba.
Key Presentations on Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2020 ASH Annual Meeting with Dr Harry Erba
Dr Harry Erba from Duke University in Durham, North Carolina, discusses key presentations on acute myeloid leukemia and myelodysplastic syndromes from the 2020 AS Annual Meeting.
CME information and select publications here.
Key Presentations on Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2020 ASH Annual Meeting with Dr Harry Erba
Dr Harry Erba from Duke University in Durham, North Carolina, discusses key presentations on acute myeloid leukemia and myelodysplastic syndromes from the 2020 AS Annual Meeting.
CME information and select publications here.
FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD
This podcast focuses on FLT3-ITD-positive acute myeloid leukemia (FLT3-ITD+ AML), featuring experts Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Canc…
Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!
Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan…
Prolonging remission in AML: current approaches & future outlooks
Today's podcast features a discussion with leading experts Harry Erba, MD, PhD, Duke University, Durham, NC, Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, on strategies to prolong r…
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts in acute myeloid leukemia (AML) as they discussed the latest updates in the field. In this podcast series, you will hear the latest advances in AML and gain an insight int…
MRD in ALL and AML: from prognostic marker to clinical endpoint
This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), from prognostic marker to clinical endpoint. Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the potential of MRD as a surrogate …
Designing Durable Remissions in Relapsed AML and Follicular Lymphoma
In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Harry Erba of Duke University and Dr. Sairah Ahmed of the University of Texas MD Anderson Cancer Center on their latest articles published in Blood on durable treatment strategies for relapsed and refractory hematologic maligna…
SEARCH ENGINE NG PODCAST
Maaari mong gamitin ang aming website upang maghanap ng mga3,827,252na mga podcast at196,200,455na mga episode ayon sa mga tao, lugar, o paksa.
Pinakamalaki ang balik ng pamumuhunan sa kaalaman, kaya nakikinig ako ng mga podcast.
‐ Benjamin "Llamacorn" Franklin
I-EDIT
Salamat sa pagtulong na mapanatiling naka-update ang database ng podcast.
